Riegman, Michelle http://orcid.org/0000-0001-7381-015X
Sagie, Liran
Galed, Chen http://orcid.org/0000-0003-3186-0428
Levin, Tom http://orcid.org/0000-0002-0369-1711
Steinberg, Noah http://orcid.org/0000-0003-1337-1479
Dixon, Scott J. http://orcid.org/0000-0001-6230-8199
Wiesner, Ulrich http://orcid.org/0000-0001-6934-3755
Bradbury, Michelle S. http://orcid.org/0000-0003-3147-4391
Niethammer, Philipp http://orcid.org/0000-0003-4175-4012
Zaritsky, Assaf http://orcid.org/0000-0002-1477-5478
Overholtzer, Michael http://orcid.org/0000-0003-3007-4986
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (GM122923, GM099970, GM127356)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA008748, CA154649, CA008748)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 28 January 2020
Accepted: 24 July 2020
First Online: 31 August 2020
Competing interests
: Memorial Sloan-Kettering Cancer Center and three investigators involved in this study (M.S.B., U.W. and M.O.) have financial interests in Elucida Oncology. Research involving C′ dots may involve one or more US or international patent applications.